Skip to main content
. 2016 Sep 19;6:33737. doi: 10.1038/srep33737

Figure 2. The loss of Nox2 expression suppresses the differentiation of miPSCs into miPSC-ECs.

Figure 2

(A) Real-time PCR shows Nox2 parallel expression with EC markers at the mRNA levels in miPSC-ECs at day 14 of differentiation (n = 3; **P < 0.01 vs. WT miPSCs). (B) Flow cytometry analysis of ECs derived from WT miPSCs and Nox2−/− miPSCs using specific antibodies to CD31 at day 14 of differentiation (n = 3; *P < 0.05 vs. WT miPSC). (C) The purified WT miPSC-ECs and Nox2−/− miPSC-ECs were measured for the expression of endothelial markers, showing the decrease of CD31 and CD144 mRNA levels in Nox2−/− miPSC-ECs (left panel). The reduced expression of CD31 and CD144 in Nox2−/− miPSC-ECs was further confirmed by immunoblotting (right panel, n = 3; *P < 0.05 vs. WT miPSC-ECs). (D) Quantitative PCR analyses and immunobloting show the decrease of VEGF and angiopoietin-1 mRNA and protein levels in Nox2−/− miPSC-ECs (n = 3; *P < 0.05, **P < 0.01 vs. WT miPSC-ECs). (E) Nox2 overexpression using Ad-Nox2 in WT miPSC-ECs and Nox2−/− miPSC-ECs, showing the increase in CD31, CD144, VEGF and Ang-1 expression at mRNA levels (n = 3; *P < 0.05, **P < 0.01).

HHS Vulnerability Disclosure